Analysts expect Avalo Therapeutics, Inc. to report revenue of 0.00 for Q3 26, against a range of 0.00 to 0.00. The most recent reported quarter, Q2 26, came in at 0.00.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 249,000.00 | 200,000.00 | 0.00 | 0.00 | 0.00 | 79,500.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -26,191.75 | -28,072.94 | -5,511.56 | 25,471.84 | ||||||||||
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -29,305.71 | -30,353.32 | -6,095.22 | 23,390.32 | ||||||||||
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -27,748.73 | -29,213.13 | -5,803.39 | 24,431.08 |
Analysts expect Avalo Therapeutics, Inc. to report earnings per share of -0.62 for Q3 26, against a range of -0.68 to -0.56. The most recent reported quarter, Q2 26, came in at -0.83, a 53.7% miss against the -0.54 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -2.83 | -2.30 | -1.25 | -1.92 | -2.19 | -0.75 | -0.98 | -0.83 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -1.11 | -0.17 | -1.16 | -1.29 | -1.52 | -1.42 | -0.99 | -0.51 | -0.56 | -0.55 | -0.57 | -0.70 | -0.37 | -0.06 | -0.87 | -1.00 | ||||||||||
| Low Estimate | -1.19 | -0.19 | -1.38 | -1.43 | -1.70 | -1.64 | -1.17 | -0.57 | -0.68 | -0.59 | -0.67 | -0.84 | -0.45 | -0.06 | -1.03 | -1.22 | ||||||||||
| Consensus Estimate | -1.15 | -0.18 | -1.27 | -1.36 | -1.61 | -1.53 | -1.08 | -0.54 | -0.62 | -0.57 | -0.62 | -0.77 | -0.41 | -0.06 | -0.95 | -1.11 |
Pull Wall Street consensus for Avalo Therapeutics, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=AVTX&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "AVTX", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=AVTX&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();